High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Challenges of Complex Karyotype and TP53

Author(s): Supriya peshin, FNU Warsha, Shagun Singh, FNU Vineesha, FNU Vishal, Marissa G Vito Cruz

This case report elucidates the clinical trajectory of a 60-year-old male with a history of mild cytopenias, subsequently diagnosed with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) characterized by a complex karyotype and a TP53 mutation. The initial diagnostic evaluation included a bone marrow biopsy revealing 34% myeloid blasts with aberrant immunophenotyping and complex cytogenetic abnormalities, including losses and gains of chromosomal regions. Genetic analysis confirmed a high Variant Allele Frequency of 80% for the TP53 mutation. The patient’s management strategy commenced with a combination of Inqovi (decitabine and cedazuridine) and Venetoclax, supported by prophylactic measures to mitigate tumor lysis syndrome and vigilant infection control. While offering a glimmer of hope for improving outcomes in this high-risk cohort, this treatment approach underscores the inherent challenges posed by the aggressive nature of the disease and the TP53 mutation’s contribution to therapeutic resistance. The case highlights the critical need for personalized treatment regimens and rigorous follow-up to optimize patient care and advance our understanding of this complex malignancy.